S 3510 · 119th Congress

Biosimilar Inspection Modernization Act of 2025

This bill asks the FDA to modernize how it inspects factories that make biosimilar drugs—which are affordable copies of expensive biologic medications like those used to treat cancer and autoimmune diseases. Right now, the FDA inspects these facilities using traditional methods that can be time-consuming and resourc…

Sponsor

Budd, Ted (R-North Carolina)

Introduced

2025-12-16

Policy area

Health

Latest action

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.